Abstract
Integrating results from genome-wide association studies (GWAS) and studies of molecular phenotypes like gene expressions, can improve our understanding of the biological functions of trait-associated variants, and can help prioritize candidate genes for downstream analysis. Using reference expression quantitative trait loci (eQTL) studies, several methods have been proposed to identify significant gene-trait associations, primarily based on gene expression imputation. Further, to increase the statistical power by leveraging substantial eQTL sharing across tissues, meta-analysis methods aggregating such gene-based test results across multiple tissues or contexts have been developed as well. However, most existing meta-analysis methods have limited power to identify associations when the gene has weaker associations in only a few tissues and cannot identify the subset of tissues in which the gene is “activated” in. For this, we developed a novel cross-tissue subset-based meta-analysis (CSTWAS) method which improves power under such scenarios and can extract the set of potentially “active” tissues. To improve applicability, CSTWAS uses only GWAS summary statistics and pre-computed correlation matrices to identify a subset of tissues that have the maximal evidence of gene-trait association. We further developed an adaptive monte-carlo procedure with the generalized Pareto distribution (GPD) to accurately estimate highly significant p-values for the test statistics. Through numerical simulations, we found that CSTWAS can maintain a well-calibrated type-I error rate, improves power especially when there is a small number of “active” tissues for a gene-trait association and identifies an accurate “active” tissue-set. By analyzing several GWAS summary statistics of three complex traits and diseases, we demonstrated that CSTWAS could identify novel biological meaningful signals while providing an interpretation of disease etiology by extracting a set of potentially “active” tissues.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Human Genome Research Institute [1 R01 HG010480-01].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Northwest Multi-Centre Research gave ethical approval for this work (approval number 16/NW/0274).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
